CXCR4 and central nervous system cancer: CXCR4 inhibition using plerixafor was therefore proposed in combination with bevacizumab (anti-vascular endothelial growth factor monoclonal antibody) for diminishing resistance to this anti-angiogenic therapy and has thus far proven safe in patients with high-grade gliomas [36].